BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9270021)

  • 1. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.
    Chen K; Braun S; Lyman S; Fan Y; Traycoff CM; Wiebke EA; Gaddy J; Sledge G; Broxmeyer HE; Cornetta K
    Cancer Res; 1997 Aug; 57(16):3511-6. PubMed ID: 9270021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileukemic activity of Flt3 ligand in murine leukemia.
    Wang A; Braun SE; Sonpavde G; Cornetta K
    Cancer Res; 2000 Apr; 60(7):1895-900. PubMed ID: 10766177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action.
    Braun SE; Chen K; Blazar BR; Orchard PJ; Sledge G; Robertson MJ; Broxmeyer HE; Cornetta K
    Hum Gene Ther; 1999 Sep; 10(13):2141-51. PubMed ID: 10498246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
    Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
    Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of retroviral-mediated gene transfer into primary human stromal cells of Flt3-ligand, interleukin 3 and GM-CSF on production of cord blood progenitor cells in long-term culture.
    Balduini A; Braun SE; Cornetta K; Lyman S; Broxmeyer HE
    Stem Cells; 1998; 16 Suppl 1():37-49. PubMed ID: 11012147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model.
    Alsheikhly AR; Zweiri J; Walmesley AJ; Watson AJ; Christmas SE
    Cancer Immunol Immunother; 2004 Nov; 53(11):946-54. PubMed ID: 15185012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer.
    Dong J; Bohinski RJ; Li YQ; Van Waes C; Hendler F; Gleich L; Stambrook PJ
    Cancer Gene Ther; 2003 Feb; 10(2):96-104. PubMed ID: 12536197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered tumor cell vaccine in a head and neck cancer model.
    Couch M; Saunders JK; O'Malley BW; Pardoll D; Jaffee E
    Laryngoscope; 2003 Mar; 113(3):552-6. PubMed ID: 12616213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
    Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
    Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM; Ni S; Tieu AT; Lieber A
    Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
    Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
    Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
    Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
    Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma.
    Shiau AL; Lin CY; Tzai TS; Wu CL
    Cancer Gene Ther; 2001 Jan; 8(1):73-81. PubMed ID: 11219496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroviral mediated gene transfer of Flt3 ligand enhances proliferation and MAP kinase activity of AML5 cells.
    Braun SE; Aronica SM; Ge Y; Takahira H; Etienne-Julan M; Lu L; Minden MD; Lyman SD; Broxmeyer HE
    Exp Hematol; 1997 Jan; 25(1):51-6. PubMed ID: 8989907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
    Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
    Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.
    Braun SE; Chen K; Foster RG; Kim CH; Hromas R; Kaplan MH; Broxmeyer HE; Cornetta K
    J Immunol; 2000 Apr; 164(8):4025-31. PubMed ID: 10754294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
    Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
    Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.